Your browser doesn't support javascript.
loading
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Lips, Esther H; Kumar, Tapsi; Megalios, Anargyros; Visser, Lindy L; Sheinman, Michael; Fortunato, Angelo; Shah, Vandna; Hoogstraat, Marlous; Sei, Emi; Mallo, Diego; Roman-Escorza, Maria; Ahmed, Ahmed A; Xu, Mingchu; van den Belt-Dusebout, Alexandra W; Brugman, Wim; Casasent, Anna K; Clements, Karen; Davies, Helen R; Fu, Liping; Grigoriadis, Anita; Hardman, Timothy M; King, Lorraine M; Krete, Marielle; Kristel, Petra; de Maaker, Michiel; Maley, Carlo C; Marks, Jeffrey R; Menegaz, Brian A; Mulder, Lennart; Nieboer, Frank; Nowinski, Salpie; Pinder, Sarah; Quist, Jelmar; Salinas-Souza, Carolina; Schaapveld, Michael; Schmidt, Marjanka K; Shaaban, Abeer M; Shami, Rana; Sridharan, Mathini; Zhang, John; Stobart, Hilary; Collyar, Deborah; Nik-Zainal, Serena; Wessels, Lodewyk F A; Hwang, E Shelley; Navin, Nicholas E; Futreal, P Andrew; Thompson, Alastair M; Wesseling, Jelle; Sawyer, Elinor J.
Afiliação
  • Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kumar T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Megalios A; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Visser LL; MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Sheinman M; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Fortunato A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Shah V; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hoogstraat M; School of Life Sciences, Arizona State University, Tempe, AZ, USA.
  • Sei E; Biodesign Center for Biocomputing, Security and Society, Arizona State University, Tempe, AZ, USA.
  • Mallo D; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Roman-Escorza M; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ahmed AA; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu M; School of Life Sciences, Arizona State University, Tempe, AZ, USA.
  • van den Belt-Dusebout AW; Biodesign Center for Biocomputing, Security and Society, Arizona State University, Tempe, AZ, USA.
  • Brugman W; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Casasent AK; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Clements K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davies HR; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Fu L; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Grigoriadis A; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hardman TM; Screening Quality Assurance Service, Public Health England, London, UK.
  • King LM; Early Cancer Unit, Hutchison/MRC Research Centre and Academic Department of Medical Genetics, Cambridge Biomedical Research Campus, University of Cambridge, Cambridge, UK.
  • Krete M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kristel P; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • de Maaker M; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • Maley CC; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • Marks JR; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Menegaz BA; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mulder L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nieboer F; Biodesign Center for Biocomputing, Security and Society, Arizona State University, Tempe, AZ, USA.
  • Nowinski S; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • Pinder S; Department of Surgery, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
  • Quist J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Salinas-Souza C; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schaapveld M; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Schmidt MK; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Shaaban AM; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Shami R; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Sridharan M; Division of Psychosocial research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zhang J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Stobart H; Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK.
  • Collyar D; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Nik-Zainal S; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, UK.
  • Wessels LFA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwang ES; Independent Cancer Patients' Voice, London, UK.
  • Navin NE; Patient Advocates in Research, Danville, CA, USA.
  • Futreal PA; Early Cancer Unit, Hutchison/MRC Research Centre and Academic Department of Medical Genetics, Cambridge Biomedical Research Campus, University of Cambridge, Cambridge, UK.
  • Thompson AM; Faculty of Electrical Engineering, Mathematics, and Computer Science, Delft University of Technology, Delft, The Netherlands.
  • Wesseling J; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • Sawyer EJ; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Genet ; 54(6): 850-860, 2022 06.
Article em En | MEDLINE | ID: mdl-35681052
ABSTRACT
Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive disease. A fundamental biologic question is whether the invasive disease arises from tumor cells in the initial DCIS or represents new unrelated disease. To address this question, we performed genomic analyses on the initial DCIS lesion and paired invasive recurrent tumors in 95 patients together with single-cell DNA sequencing in a subset of cases. Our data show that in 75% of cases the invasive recurrence was clonally related to the initial DCIS, suggesting that tumor cells were not eliminated during the initial treatment. Surprisingly, however, 18% were clonally unrelated to the DCIS, representing new independent lineages and 7% of cases were ambiguous. This knowledge is essential for accurate risk evaluation of DCIS, treatment de-escalation strategies and the identification of predictive biomarkers.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Ductal de Mama / Carcinoma Intraductal não Infiltrante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Ductal de Mama / Carcinoma Intraductal não Infiltrante Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Nat Genet Assunto da revista: GENETICA MEDICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda